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A bs tr ac t
Background
Treatment with the direct thrombin inhibitor bivalirudin, as compared with hepa-
rin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia 
while reducing hemorrhagic complications in patients with stable angina and non−ST-
segment elevation acute coronary syndromes who are undergoing percutaneous coro-
nary intervention (PCI). The safety and efficacy of bivalirudin in high-risk patients 
are unknown.
Methods
We randomly assigned 3602 patients with ST-segment elevation myocardial infarc-
tion who presented within 12 hours after the onset of symptoms and who were 
undergoing primary PCI to treatment with heparin plus a glycoprotein IIb/IIIa in-
hibitor or to treatment with bivalirudin alone. The two primary end points of the 
study were major bleeding and combined adverse clinical events, defined as the com-
bination of major bleeding or major adverse cardiovascular events, including death, 
reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter 
referred to as net adverse clinical events) within 30 days.
Results
Anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein 
IIb/IIIa inhibitors, resulted in a reduced 30-day rate of net adverse clinical events 
(9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI] 0.63 to 0.92; P = 0.005), 
owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 
0.46 to 0.77; P<0.001). There was an increased risk of acute stent thrombosis within 
24 hours in the bivalirudin group, but no significant increase was present by 30 days. 
Treatment with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa 
inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes 
(1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P = 0.03) and death from all 
causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P = 0.047). 
Conclusions
In patients with ST-segment elevation myocardial infarction who are undergoing 
primary PCI, anticoagulation with bivalirudin alone, as compared with heparin 
plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates 
of major bleeding and net adverse clinical events. (ClinicalTrials.gov number, 
NCT00433966.)
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Primary percutaneous coronary in-tervention (PCI) in patients with evolving ST-segment elevation myocardial infarction de-
creases infarct size and the rates of recurrent 
ischemia, reinfarction, and stroke and improves 
survival, as compared with pharmacologic reper-
fusion therapy.1,2 Nonetheless, the prognosis after 
primary PCI has remained essentially unchanged 
over the past decade, with neither stents nor other 
novel devices or drugs improving survival beyond 
that achievable with balloon angioplasty alone.3-8 
Treatment with glycoprotein IIb/IIIa inhibitors may 
decrease the short- and long-term risk of death,9,10 
and these agents are used in more than 90% of 
patients who undergo primary PCI in the United 
States and in the majority of such patients in Eu-
rope.11,12 Nonetheless, glycoprotein IIb/IIIa inhib-
itors increase the risk of hemorrhagic complica-
tions and thrombocytopenia,3,10,13-15 which have 
been strongly associated with early and late mor-
tality.15-19
The direct thrombin inhibitor bivalirudin (An-
giomax, the Medicines Company), when used in-
stead of heparin plus glycoprotein IIb/IIIa inhibi-
tors, has been shown in large-scale, randomized 
trials to reduce major and minor bleeding and 
thrombocytopenia while resulting in similar rates 
of ischemia after PCI in patients with stable an-
gina, those with unstable angina, and those with 
non−ST-segment elevation myocardial infarc-
tion.20-23 Whether bivalirudin is safe and effective 
for patients with ST-segment elevation myocar-
dial infarction who are undergoing primary PCI 
has not, to our knowledge, been studied. We there-
fore performed a large-scale study to evaluate the 
clinical value of bivalirudin in patients with ST-
segment elevation myocardial infarction.
Me thods
Trial
The Harmonizing Outcomes with Revasculariza-
tion and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) study was a prospective, open-
label, randomized, multicenter trial that compared 
bivalirudin alone with heparin plus a glycopro-
tein IIb/IIIa inhibitor in patients with ST-segment 
elevation myocardial infarction who were under-
going primary PCI. The trial was designed by the 
principal investigator (Dr. Stone), executive com-
mittee, and pharmacology committee and was 
sponsored and managed by the Cardiovascular Re-
search Foundation, a nonprofit foundation affili-
ated with Columbia University (receiving funding 
from many commercial entities that make products 
for use in cardiovascular medicine, in addition to 
various other sources), with grant support from 
Boston Scientific and the Medicines Company. 
Other than supplying financial support and the 
drugs and devices, the funding companies were 
not involved with study processes, including site 
selection and management, data collection, and 
analysis. The principal investigator had unrestrict-
ed access to the data after the database was locked, 
controlled the decision to publish, prepared the 
manuscript, and vouches for the integrity and com-
pleteness of the trial report. No agreements exist 
regarding confidentiality of the data among the 
funding companies, the sponsor, and the investi-
gators.
Patient Population
Consecutive patients 18 years of age or older who 
presented within 12 hours after the onset of symp-
toms and who had ST-segment elevation of 1 mm 
or more in two or more contiguous leads, new left 
bundle-branch block, or true posterior myocardial 
infarction were considered for enrollment. The 
principal exclusion criteria were contraindications 
to the study medications; prior administration of 
thrombolytic agents, bivalirudin, glycoprotein IIb/
IIIa inhibitors, low-molecular-weight heparin, or 
fondaparinux for the present admission (although 
prior unfractionated heparin was allowed); current 
use of warfarin; history of bleeding diathesis, co-
agulopathy, heparin-induced thrombocytopenia, 
intracerebral mass, aneurysm, arteriovenous mal-
formation, or hemorrhagic stroke; stroke or tran-
sient ischemic attack within the previous 6 months 
or any permanent neurologic deficit; refusal to re-
ceive blood transfusions; gastrointestinal or gen-
itourinary bleeding within the previous 2 months; 
major surgery within the previous 6 weeks; a known 
platelet count of less than 100,000 cells per cubic 
millimeter or a hemoglobin level of less than 10 g 
per deciliter, a planned elective surgical procedure 
that would necessitate an interruption in treatment 
with thienopyridines during the first 6 months 
after enrollment; coronary stent implantation 
within the previous 30 days; and noncardiac co-
existing conditions that could limit life expectancy 
to less than 1 year or that might interfere with 
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compliance with the protocol. The study was ap-
proved by the institutional review board or ethics 
committee at each participating center, and all 
patients gave written informed consent.
Study Protocol and Randomization
Patients were randomly assigned, in an open-label 
fashion and in a 1:1 ratio, to treatment with un-
fractionated heparin plus a glycoprotein IIb/IIIa 
inhibitor (the control group) or to treatment with 
bivalirudin alone (Fig. 1). Heparin was adminis-
tered as an intravenous bolus of 60 IU per kilogram 
of body weight, with subsequent boluses targeted 
to an activated clotting time of 200 to 250 seconds. 
Bivalirudin was administered as an intravenous 
bolus of 0.75 mg per kilogram, followed by an infu-
sion of 1.75 mg per kilogram per hour. If heparin 
was administered in a patient in the bivalirudin 
group, bivalirudin was started 30 minutes later but 
in all cases before PCI. Both antithrombin agents 
were discontinued, as specified by the protocol, 
at the completion of angiography or PCI but could 
be continued at low doses if they were clinically 
indicated. A glycoprotein IIb/IIIa inhibitor was 
administered before PCI in all the patients in the 
control group but was to be administered in the 
bivalirudin group only in patients with no reflow 
or with giant thrombus after PCI. Either abcix-
imab (a bolus of 0.25 mg per kilogram followed 
by an infusion of 0.125 μg per kilogram per min-
ute; maximum dose, 10 μg per minute) or double-
bolus eptifibatide (a bolus of 180 μg per kilogram 
followed by an infusion of 2.0 μg per kilogram 
per minute, with a second bolus given 10 minutes 
after the first; no maximum dose prespecified), 
adjusted for renal impairment according to the 
label, was permitted at the discretion of the in-
vestigator and was continued for 12 hours (ab-
ciximab) or 12 to 18 hours (eptifibatide).
Aspirin (324 mg given orally or 500 mg admin-
istered intravenously) was given in the emergency 
room, after which 300 to 325 mg was given orally 
every day during the hospitalization, and 75 to 
81 mg every day thereafter indefinitely. A loading 
dose of clopidogrel (either 300 mg or 600 mg, at 
the discretion of the investigator), or ticlopidine 
(500 mg), in the case of allergy to clopidogrel, was 
administered before catheterization, followed by 
75 mg orally every day for at least 6 months (1 year 
or longer recommended).
Telephone randomization was performed with 
the use of a computerized, interactive voice-
response system and a dynamic (minimization) 
allocation scheme that balanced the assignments 
for the administration of heparin before random-
ization; the administration of 300 mg or 600 mg 
of clopidogrel or 500 mg of ticlopidine before cath-
eterization; planned administration of abciximab 
or eptifibatide for patients assigned to the con-
trol group; and the location of the study site (in 
the United States or outside the United States).
Emergency coronary angiography with left ven-
triculography was performed after randomization, 
followed by triage, at the discretion of the phy-
sician, to PCI, coronary-artery bypass grafting 
(CABG), or medical management, as described 
previously.3 After patency was restored in the in-
farct-related vessel, eligible patients were randomly 
assigned again, in a 3:1 ratio, to either paclitaxel-
eluting stents (TAXUS Express,2 Boston Scientific) 
or uncoated, bare-metal stents that were identical 
in appearance (Express,2 Boston Scientific). The 
protocol specified that enrollment would continue 
until 3000 patients had been randomly assigned 
to a treatment group in this second part of the 
study. Clinical follow-up was performed at 30 days 
(±7 days), 6 months (±14 days), and 1 year (±14 
days) and then yearly for a total of 5 years. Pre-
specified analyses of the primary end points were 
planned at 30 days for the first randomization 
(the pharmacologic component of the study) and 
at 1 year for the second randomization (the stent 
component). The results of the second random-
ization currently remain blinded, and the 30-day 
results reported here are based on pooled data for 
the stent groups. There were no significant inter-
actions between stent type and the primary end 
points at 30 days in the pharmacologic compo-
nent, according to an unblinded, independent 
statistical monitoring group.
Statistical Analysis
Two primary 30-day end points were prespecified: 
major bleeding (not related to coronary-artery by-
pass grafting) and combined adverse clinical 
events, defined as the combination of major bleed-
ing or a composite of major adverse cardiovascu-
lar events, including death, reinfarction, target-
vessel revascularization for ischemia, and stroke 
(hereinafter referred to as net adverse clinical 
events). Major bleeding was defined as intracra-
nial or intraocular hemorrhage; bleeding at the 
access site, with a hematoma that was 5 cm or 
larger or that required intervention; a decrease in 
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the hemoglobin level of 4 g per deciliter or more 
without an overt bleeding source or 3 g per deci-
liter or more with an overt bleeding source; re-
operation for bleeding; or blood transfusion. Bleed-
ing was also assessed and adjudicated on the basis 
of the Thrombolysis in Myocardial Infarction 
(TIMI) and Global Utilization of Streptokinase 
and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO) scales. Major adverse 
cardiovascular events have been defined previous-
ly.24 Death from cardiac causes was defined as 
death due to acute myocardial infarction, cardiac 
perforation or pericardial tamponade, arrhythmia 
or conduction abnormality, stroke, procedural 
complications, or any death for which a cardiac 
cause could not be ruled out. Death from noncar-
diac causes included bleeding-related death. Stent 
thrombosis was defined as the definite or prob-
able occurrence of a stent-related thrombotic event 
according to the Academic Research Consortium 
classification.25 An independent clinical events 
committee that was unaware of the treatment as-
signments adjudicated all end-point events by re-
viewing the medical records.
The primary analyses were performed for all 
patients who underwent randomization, accord-
ing to the intention-to-treat principle; secondary 
analyses were performed for the patients who un-
derwent primary PCI. Sequential noninferiority 
and superiority analysis with hierarchical end-
point testing for both primary end points was 
prespecified, with type I error controlled by the 
Benjamini–Hochberg procedure.26 Noninferiority 
tests were based on the upper boundary of the 
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Figure 1. Randomization, Management Strategy, and Follow-up at 30 Days. 
Two additional patients who did not give written consent were randomly assigned to bivalirudin, but the study drug 
was not administered and no data were collected for these patients. After coronary arteriography, a second round  
of randomization was performed, with eligible patients assigned to receive a paclitaxel-eluting stent or a bare-metal 
stent (not shown). Results of this randomization remain blinded. CABG denotes coronary-artery bypass grafting,  
GP glycoprotein, PCI percutaneous coronary intervention, and STEMI ST-segment elevation myocardial infarction.
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two-sided 95% confidence interval, with the use 
of binomial proportions. The noninferiority mar-
gins for major bleeding and net adverse clinical 
events were prespecified at 1% and 3.2%, respec-
tively. A two-sided alpha level of 0.05 was used for 
superiority testing. Assuming true 30-day event 
rates for major bleeding and net adverse clinical 
events of 9% and 12%, respectively, in the control 
group and 6% and 9%, respectively, in the bivali-
rudin group, with 1700 patients in each group, the 
trial had 99% power to show the superiority of 
bivalirudin for reducing the rate of major bleeding 
and 80% power to show its superiority for reduc-
ing the rate of net adverse clinical events.
Categorical outcomes were compared by means 
of the chi-square test or Fisher’s exact test. Con-
tinuous variables were compared by means of the 
Wilcoxon rank-sum test. In addition to the pri-
mary analysis, which was based on binomial pro-
portions, time-to-event outcomes, determined with 
Kaplan−Meier methods, were compared by means 
of the log-rank test.
R esult s
Patients and Procedures
Between March 25, 2005, and May 7, 2007, a total 
of 3602 patients, at 123 centers in 11 countries, 
who had ST-segment elevation myocardial infarc-
tion and were undergoing primary PCI were ran-
domly assigned to treatment with heparin plus a 
glycoprotein IIb/IIIa inhibitor (1802 patients) or 
with bivalirudin alone (1800 patients) (Fig. 1). After 
emergency angiography, the primary management 
strategy was primary PCI in 92.7% of the patients, 
deferred PCI in 0.2%, primary CABG in 1.7%, and 
medical management in 5.3%.
The baseline features of the groups were well 
matched (Table 1). The median age was 60.2 years, 
and 76.6% of the patients were men. The infarct-
related vessel was the left anterior descending ar-
tery in 40.7% of the patients who were undergoing 
primary PCI, and stents were implanted in 95.5% 
of those patients. Compliance with protocol-speci-
fied study medications was high (Table 2). Un-
fractionated heparin (typically a bolus without 
infusion) was administered before cardiac cathe-
terization in approximately two thirds of the pa-
tients who were assigned to treatment with bivali-
rudin. A 600-mg loading dose of clopidogrel was 
used almost twice as frequently as a 300-mg dose. 
Glycoprotein IIb/IIIa inhibitors were administered 
in 129 patients (7.2%) who were assigned to bi-
valirudin treatment — in 47 because of a sus-
tained absence of reflow after PCI, in 32 because 
of giant thrombus after PCI, and in the rest for 
various other clinical indications.
Clinical Outcomes
At 30 days, patients who were assigned to receive 
bivalirudin alone, as compared with those who 
were assigned to receive heparin plus a glycopro-
tein IIb/IIIa inhibitor, had a significantly reduced 
rate of net adverse clinical events (9.2% vs. 12.1%; 
relative risk, 0.76; 95% confidence interval [CI], 
0.63 to 0.92; P = 0.005), owing to a lower rate of 
major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 
95% CI, 0.46 to 0.77; P<0.001), with similar rates 
of major adverse cardiovascular events (5.4% and 
5.5%, respectively; relative risk in the bivalirudin 
group, 0.99; 95% CI, 0.76 to 1.30; P = 0.95) (Table 3 
and Fig. 2). In a post hoc analysis, with the exclu-
sion of large hematomas from the protocol defi-
nition, the rate of major bleeding was reduced from 
7.8% with heparin plus glycoprotein IIb/IIIa inhibi-
tors to 4.7% with bivalirudin (P<0.001). Bivaliru-
din, as compared with heparin plus glycoprotein 
IIb/IIIa inhibitors, also reduced hemorrhagic com-
plications as defined by the TIMI and GUSTO 
scales, thrombocytopenia, and the need for blood 
transfusions (Table 3). Among patients in the con-
trol group, the peak activated clotting time did 
not differ significantly between those with major 
bleeding and those without major bleeding (me-
dian, 273 seconds and 263 seconds, respectively; 
P = 0.12).
Treatment with bivalirudin, as compared with 
heparin plus glycoprotein IIb/IIIa inhibitors, re-
sulted in significantly lower 30-day rates of death 
from cardiac causes (1.8% vs. 2.9%; relative risk, 
0.62; 95% CI, 0.40 to 0.95; P = 0.03) and death from 
all causes (2.1% vs. 3.1%; relative risk, 0.66; 
95% CI, 0.44 to 1.00; P = 0.047); rates of reinfarc-
tion, target-vessel revascularization, and stroke 
were not significantly different (Table 3 and Fig. 2). 
There were no significant differences in the peak 
creatine kinase level or creatine kinase MB frac-
tion between the bivalirudin group and the group 
that received heparin plus glycoprotein IIb/IIIa 
inhibitors (median peak creatine kinase level, 
1433.0 U per liter and 1428.5 U per liter, respec-
tively; P = 0.79; median peak creatine kinase MB 
fraction, 162.8 U per liter and 160.1 U per liter, 
respectively; P = 0.98). There were no significant 
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interactions between the treatment assignment 
and either preprocedural unfractionated-heparin 
use or clopidogrel loading dose with respect to 
major adverse cardiovascular events or major bleed-
ing (Table 4).
Among 3124 patients in whom stents were suc-
cessfully implanted, the overall rate of stent throm-
bosis at 30 days did not differ significantly be-
tween the group that received bivalirudin and the 
group that received heparin plus a glycoprotein 
IIb/IIIa inhibitor (2.5% and 1.9%, respectively; 
P = 0.30). However, in a prespecified analysis, with-
in the first 24 hours, stent thrombosis occurred in 
17 more patients in the bivalirudin group than in 
the group receiving heparin plus a glycoprotein 
IIb/IIIa inhibitor (1.3% vs. 0.3%, P<0.001), where-
as between 24 hours and 30 days, stent thrombo-
sis occurred in 7 fewer patients in the bivalirudin 
group (1.2% vs. 1.7%, P = 0.28). Nonetheless, pa-
tients in whom PCI was performed and who were 
Table 1. Baseline Characteristics of the Study Population.*
Characteristic
Heparin plus a  
Glycoprotein IIb/IIIa  
Inhibitor (N = 1802)
Bivalirudin Alone 
(N = 1800)
Age — yr
Median 60.7 59.8
Range 21.6–91.6 26.0–92.3
Male sex — no. (%) 1372 (76.1) 1388 (77.1)
Diabetes — no./total no. (%)
Any 312/1800 (17.3) 281/1799 (15.6)
Insulin-requiring 87/1800 (4.8) 72/1799 (4.0)
Hypertension — no./total no. (%) 993/1800 (55.2) 931/1799 (51.8)
Hyperlipidemia — no./total no. (%) 769/1800 (42.7) 781/1798 (43.4)
Current smoker — no./total no. (%) 807/1792 (45.0) 845/1789 (47.2)
Prior myocardial infarction — no./total no. (%) 205/1800 (11.4) 187/1799 (10.4)
Prior percutaneous coronary intervention — no./total no. (%) 198/1800 (11.0) 188/1799 (10.5)
Prior coronary-artery bypass grafting — no./total no. (%) 46/1800 (2.6) 59/1799 (3.3)
Weight — kg
Median 80.0 80.0
Interquartile range 71.0–90.0 71.0–90.3
Interval from symptom onset to hospital arrival — hr
Median 2.1 2.2
Interquartile range 1.3–3.9 1.3–4.0
Killip class II, III, or IV — no./total no. (%) 152/1797 (8.5) 153/1795 (8.5)
Renal insufficiency — no./total no. (%)† 292/1676 (17.4) 262/1661 (15.8)
Anemia — no./total no. (%)‡ 181/1692 (10.7) 175/1693 (10.3)
Thrombocytopenia — no./total no. (%)§ 80/1733 (4.6) 64/1729 (3.7)
Left ventricular ejection fraction — %¶
Median 50 50
Interquartile range 41−59 45−60
* There were no significant differences between groups, except for hypertension (P = 0.04).
† Renal insufficiency was defined as a creatinine clearance of less than 60 ml per minute as calculated at baseline by the 
Cockcroft–Gault equation.
‡ Anemia was defined, according to the World Health Organization criteria, as a hematocrit value at initial presentation 
of less than 39% for men and less than 36% for women.
§ Thrombocytopenia was defined as less than 150,000 cells per cubic millimeter at baseline.
¶ Left ventricular ejection fraction was assessed visually on the contrast-enhanced left ventriculogram obtained at baseline. 
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Table 2. Procedures and Study Medications.*
Variable
Heparin plus a  
Glycoprotein IIb/IIIa  
Inhibitor (N = 1802)
Bivalirudin Alone  
(N = 1800)
Infarct-related artery — no./total no. (%)†
Left anterior descending 747/1778 (42.0) 700/1781 (39.3)
Left circumflex 269/1778 (15.1) 293/1781 (16.5)
Right 738/1778 (41.5) 757/1781 (42.5)
Left main 7/1778 (0.4) 13/1781 (0.7)
Saphenous-vein graft 17/1778 (1.0) 17/1781 (1.0)
Internal thoracic 0/1778 1/1781 (0.1)
Stent implanted (among PCI patients) — no./total no. (%) 1553/1628 (95.4) 1571/1643 (95.6)
Heparin before procedure — no./total no. (%) 1371/1798 (76.3) 1182/1797 (65.8)
Antithrombin during procedure — no./total no. (%)
Heparin 1778/1798 (98.9) 46/1796 (2.6)
Bivalirudin 4/1787 (0.2) 1741/1797 (96.9)
Peak activated clotting time — sec
Median 264 357
Interquartile range 228–320 300–402
Glycoprotein IIb/IIIa inhibitor use — no./total no. (%)
During cardiac catheterization 1699/1798 (94.5) 129/1792 (7.2)
During primary PCI 1623/1661 (97.7) 126/1674 (7.5)
Abciximab 863/1661 (52.0) 72/1674 (4.3)
Eptifibatide 757/1661 (45.6) 53/1674 (3.2)
Tirofiban 3/1661 (0.2) 2/1674 (0.1)
Aspirin use — no./total no. (%)
Before admission 486/1798 (27.0) 482/1795 (26.9)
During hospitalization 1795/1798 (99.8) 1791/1797 (99.7)
At discharge 1697/1748 (97.1) 1729/1762 (98.1)
Thienopyridine use — no./total no. (%)
Before admission 80/1798 (4.4) 63/1795 (3.5)
Loading dose at time of admission
Clopidogrel, 300 mg 618/1798 (34.4) 595/1797 (33.1)
Clopidogrel, 600 mg 1091/1798 (60.7) 1125/1797 (62.6)
Clopidogrel, other or unknown 89/1798 (4.9) 77/1797 (4.3)
Ticlopidine 7/1797 (0.4) 8/1795 (0.4)
During hospitalization 1766/1798 (98.2) 1772/1796 (98.7)
At discharge 1621/1748 (92.7) 1652/1764 (93.7)
Other medications at discharge — no./total no. (%)
Beta-blockers 1575/1747 (90.2) 1598/1763 (90.6)
ACE inhibitors or angiotensin-receptor blockers 1437/1749 (82.2) 1402/1763 (79.5)
Statins 1641/1749 (93.8) 1652/1763 (93.7)
* ACE denotes angiotensin-converting enzyme, and PCI percutaneous coronary intervention.
† Some patients had more than one vessel treated during the index procedure.
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assigned to receive bivalirudin rather than hepa-
rin plus a glycoprotein IIb/IIIa inhibitor had lower 
30-day rates of death from cardiac causes (1.8% 
vs. 2.8%; relative risk, 0.63; 95% CI, 0.40 to 0.99; 
P = 0.045), major bleeding (5.1% vs. 8.5%; relative 
risk, 0.59; 95% CI, 0.46 to 0.77; P<0.001), and net 
adverse clinical events (9.2% vs. 12.2%; relative 
risk, 0.75; 95% CI, 0.62 to 0.92; P = 0.005).
Among the 25 patients in whom stent throm-
bosis developed within 24 hours, 2 patients died 
(8.0%), including 1 in each randomized group. In 
the entire study cohort, of the 93 patients who died 
within 30 days, death was preceded by major 
bleeding in 26 patients, 8 of whom were in the 
bivalirudin group (hazard ratio for death among 
patients with vs. those without major bleeding, 
9.12; 95% CI, 5.73 to 14.52; P<0.001) and by defi-
nite stent thrombosis in 5 patients, 1 of whom was 
in the bivalirudin group (hazard ratio for death 
among patients with vs. those without definite 
stent thrombosis, 5.54; 95% CI, 2.24 to 13.69; 
P<0.001).
Discussion
In this prospective, randomized trial involving 
patients with ST-segment elevation myocardial 
infarction who were undergoing primary PCI, 
treatment with the direct thrombin inhibitor bi-
valirudin (with glycoprotein IIb/IIIa inhibitors ad-
ministered in 7.2% of the patients because of sub-
optimal results of the PCI), as compared with 
treatment with heparin plus the routine use of 
glycoprotein IIb/IIIa inhibitors, improved event-
free survival at 30 days, owing to a significant re-
duction in major bleeding. The rates of major ad-
verse cardiovascular events were similar in the two 
treatment groups. Bivalirudin reduced the rate of 
major bleeding, as classified not only by the pro-
tocol definition but also by the laboratory-based 
TIMI scale and the clinical GUSTO scale, and in 
addition reduced the rates of thrombocytopenia 
and blood transfusion, despite the significantly 
higher peak activated clotting time among patients 
treated with bivalirudin. Moreover, random as-
signment to bivalirudin alone as compared with 
heparin plus glycoprotein IIb/IIIa inhibitors sig-
nificantly reduced the rates of death from cardiac 
causes and from all causes at 30 days.
The reduction in mortality with bivalirudin as 
compared with heparin plus glycoprotein IIb/IIIa 
inhibitors in the present trial may be attributable 
to the prevention of iatrogenic hemorrhagic com-
plications. Previous trials have documented the 
independent relationship between major bleeding 
(with or without blood transfusions) and subse-
quent death.16-19 Major bleeding was a more pow-
erful predictor of death than periprocedural myo-
cardial infarction after PCI in the Randomized 
Evaluation of PCI Linking Angiomax to Reduced 
Clinical Events 2 (REPLACE-2) trial, and the re-
duction in bleeding with bivalirudin as compared 
with heparin plus glycoprotein IIb/IIIa inhibitors 
resulted in a trend toward reduced late mortality 
after PCI among the relatively low-risk patients in 
that study.27 In the present trial, more deaths oc-
curred after major bleeding (26 deaths) than after 
reinfarction (10) or definite stent thrombosis (5). 
The 40% relative reduction in major bleeding in 
the bivalirudin group as compared with the group 
that received heparin plus a glycoprotein IIb/IIIa 
inhibitor, with similar rates of ischemic complica-
tions, may thus explain the observed improvement 
in survival with bivalirudin in patients with ST-
segment elevation myocardial infarction, who are 
at higher risk than the patients in the REPLACE-2 
trial. Moreover, anticoagulation with bivalirudin 
reduced the occurrence of severe thrombocytope-
nia, which has also been strongly associated with 
death among patients with ST-segment elevation 
myocardial infarction and with PCI.14,15
Among patients in whom a stent was success-
fully implanted, assignment to bivalirudin, as 
compared with heparin plus glycoprotein IIb/IIIa 
inhibitors, resulted in 17 more episodes of stent 
thrombosis within the first 24 hours, represent-
ing a significant 1.0% absolute increase, which 
was partially offset by 7 fewer events in the pa-
tients treated with bivalirudin between 24 hours 
and 30 days (absolute reduction, 0.5%). The early 
increase in stent thrombosis with bivalirudin alone 
may be explained by adenosine diphosphate– 
induced platelet activation before maximal thieno-
pyridine blockade of the P2Y12 receptor28 or by 
residual thrombin activity after the discontinua-
tion of bivalirudin. However, although the increase 
in acute thrombotic events probably underlies the 
increased risk of major adverse cardiovascular 
events that was noted on the first day among pa-
tients treated with bivalirudin, the overall 30-day 
rates of reinfarction were not increased — 1.8% 
in each group — and only 2 of the 93 deaths in 
the study occurred after acute stent thrombosis 
(1 in each randomized group). The prognostic im-
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Table 3. Clinical Outcomes at 30 Days.
Outcome
Heparin plus a  
Glycoprotein IIb/IIIa Inhibitor 
(N = 1802)
Bivalirudin 
Alone 
(N = 1800) P Value
Intention-to-treat population
No. of patients 1802 1800
Net adverse clinical events (primary end point) — no. (%) 218 (12.1) 166 (9.2) 0.005
Bleeding end points 
Protocol — no. (%)
Major bleeding, non–CABG-related (primary end 
point)
149 (8.3) 89 (4.9) <0.001
Major bleeding, including CABG-related 195 (10.8) 122 (6.8) <0.001
Blood transfusion — no. (%) 63 (3.5) 37 (2.1) 0.009
TIMI classification — no. (%)
Major bleeding 91 (5.0) 55 (3.1) 0.002
Minor bleeding 82 (4.6) 51 (2.8) 0.006
Major or minor bleeding 173 (9.6) 106 (5.9) <0.001
GUSTO classification — no. (%)
Life-threatening or severe bleeding 11 (0.6) 8 (0.4) 0.49
Moderate bleeding 91 (5.0) 55 (3.1) 0.002
Life-threatening, severe, or moderate bleeding 101 (5.6) 63 (3.5) 0.002
Thrombocytopenia — no./total no. (%)*
Moderate (<100,000 platelets/mm3) 48/1653 (2.9) 19/1665 (1.1) 0.003
Severe (<50,000 platelets/mm3) 15/1653 (0.9) 5/1665 (0.3) 0.02
Profound (<20,000 platelets/mm3) 6/1653 (0.4) 0/1665 0.02
Major adverse cardiovascular events — no. (%) 99 (5.5) 98 (5.4) 0.95
Death 56 (3.1) 37 (2.1) 0.047
Cardiac causes 52 (2.9) 32 (1.8) 0.03
Noncardiac causes 4 (0.2) 5 (0.3) 0.75
Reinfarction 32 (1.8) 33 (1.8) 0.90
Q-wave 22 (1.2) 25 (1.4) 0.66
Non–Q-wave 12 (0.7) 8 (0.4) 0.37
Revascularization of target vessel for ischemia 35 (1.9) 47 (2.6) 0.18
Stroke 11 (0.6) 13 (0.7) 0.68
Primary PCI population
No. of patients 1662 1678
Net adverse clinical events — no. (%) 203 (12.2) 154 (9.2) 0.005
Major bleeding, non–CABG-related — no. (%) 142 (8.5) 85 (5.1) <0.001
Major adverse cardiovascular events — no. (%) 90 (5.4) 90 (5.4) 0.95
Death 49 (2.9) 33 (2.0) 0.067
Cardiac causes 47 (2.8) 30 (1.8) 0.045
Noncardiac causes 2 (0.1) 3 (0.2) 1.0
Reinfarction 30 (1.8) 33 (2.0) 0.73
Revascularization of target vessel for ischemia 35 (2.1) 47 (2.8) 0.19
Stroke 8 (0.5) 8 (0.5) 0.98
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plications of acute stent thrombosis that occurs 
early in the hospital phase in closely monitored 
patients who have undergone primary PCI for ST-
segment elevation myocardial infarction and that 
affects a previously infarcted myocardial territory 
may thus differ from the implications of subacute 
stent thrombosis or acute thrombosis that occurs 
after discharge from the hospital in patients who 
have undergone elective PCI and whose left ven-
tricular function was well preserved. Most impor-
tant, the rate of death from cardiac causes (in-
cluding deaths due to stent thrombosis) among 
patients who were treated with heparin plus a gly-
coprotein IIb/IIIa inhibitor surpassed that among 
patients treated with bivalirudin by day 7, and by 
30 days, a significant 37.9% relative reduction in 
death from cardiac causes (an absolute decrease of 
1.1%) was seen in the group treated with bivaliru-
din. Further investigation is warranted to deter-
mine whether the risk of early stent thrombosis 
can be mitigated by treatment with more rapid-
ly acting and potent thienopyridine agents,29,30 
a longer course of bivalirudin, or both, without 
increasing the risk of bleeding. Pending such stud-
ies, the 1% incremental risk of stent thrombosis 
within the first 24 hours, with no significant dif-
ference in the rates at 30 days, must be placed in 
the context of the decrease in the rate of major 
bleeding and the subsequent 1% absolute reduc-
tion in mortality from cardiac causes that were 
achieved with the abbreviated use of bivalirudin 
(i.e., only during PCI) as compared with heparin 
plus glycoprotein IIb/IIIa inhibitors.
The present study has several strengths, includ-
ing the enrollment of a broad cross section of pa-
tients. Nonetheless, several limitations should be 
noted. First, the logistic complexities of the trial 
necessitated an open-label design, introducing 
potential bias. However, compliance with the pro-
tocol procedure and the study medications was 
high, and the rate of provisional use of glycopro-
tein IIb/IIIa inhibitors in the bivalirudin group 
was low and similar to that in the double-blind 
REPLACE-2 trial.20 The relative reductions in hem-
orrhagic complications with bivalirudin as com-
pared with heparin plus glycoprotein IIb/IIIa in-
hibitors in the present trial were also similar to 
those in the REPLACE-2 trial.20 Potential bias was 
further mitigated by the use of blinded core labo-
ratories and a clinical-event adjudication commit-
tee that required original-source documentation 
for event verification. Second, a heparin bolus was 
administered in the emergency room to approxi-
mately two thirds of the patients, with bivalirudin 
most commonly started in the cardiac catheter-
ization laboratory 30 minutes later, before PCI. 
Interaction testing, however, showed that admin-
istration of bivalirudin significantly reduced major 
bleeding independently of preprocedural admin-
istration of heparin, and preprocedural adminis-
tration of heparin before bivalirudin was associ-
ated with a weak trend toward reduced major 
adverse cardiovascular events at 30 days. Third, the 
trial was underpowered for low-frequency end 
points, including death. However, the mechanis-
tic underpinnings for the observed reduction in 
Table 3. (Continued.)
Outcome
Heparin plus a  
Glycoprotein IIb/IIIa Inhibitor 
(N = 1802)
Bivalirudin 
Alone 
(N = 1800) P Value
Patients with stents implanted
No. of patients 1553 1571
Stent thrombosis, protocol definition — no. (%)† 30 (1.9) 39 (2.5) 0.30
Definite 22 (1.4) 35 (2.2) 0.09
Probable 8 (0.5) 4 (0.3) 0.24
Acute (≤24 hr) 4 (0.3) 21 (1.3) <0.001
Subacute (>24 hr–30 days) 26 (1.7) 19 (1.2) 0.28
* Patients with a baseline platelet count of less than 150,000 cells per cubic millimeter were not included in the analysis. 
CABG denotes coronary-artery bypass grafting, GUSTO Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries, PCI percutaneous coronary intervention, and TIMI Thrombolysis in Myocardial 
Infarction. 
† The protocol definition of stent thrombosis was definite or probable thrombosis occurring within 30 days, according to 
the Academic Research Consortium criteria.
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the rate of death with bivalirudin (i.e., reduced 
risks of bleeding, transfusion, and thrombocyto-
penia), in concert with the consistency of our re-
sults with those of earlier studies,20-23 provide 
reassurance that this finding is probably valid. 
Fourth, reinfarction may be difficult to detect after 
primary PCI, although the nearly identical peak 
levels of cardiac enzymes after PCI in the two 
treatment groups suggest that there was no dif-
ference in the rate of reinfarction. Finally, although 
an independent, unblinded statistical monitoring 
group has found no interactions between the type 
of stent used and the randomly assigned study 
drug for the primary 30-day end points, longer-
term follow-up, including unblinding of the stent 
randomization data at 1 year, is required to evalu-
ate thoroughly the effect of bivalirudin in patients 
with ST-segment elevation myocardial infarction 
who are undergoing primary PCI.
In conclusion, our trial shows that in patients 
with evolving ST-segment elevation myocardial 
infarction who are undergoing primary PCI, the 
36p6
15
N
et
 A
dv
er
se
 C
lin
ic
al
 E
ve
nt
s 
(%
)
Net Adverse Clinical Events
Major Adverse Cardiovascular Events
Major Bleeding
Death from Cardiac and Noncardiac Causes
8
14
13
12
11
10
9
7
6
4
3
1
5
2
0
0 5 10 15 20 25 30
Bivalirudin alone
Heparin plus GP IIb/IIIa
Days
A
No. at Risk
Bivalirudin alone
Heparin plus
GP IIb/IIIa
1800
1802
1660
1635
1633
1591
1626
1578
1620
1569
1607
1552
1544
1482
12
M
aj
or
 B
le
ed
in
g 
(%
)
8
11
10
9
7
6
4
3
1
5
2
0
0 5 10 15 20 25 30
Bivalirudin alone
Heparin plus GP IIb/IIIa
Days
B
No. at Risk
Bivalirudin alone
Heparin plus
GP IIb/IIIa
1800
1802
1697
1651
1675
1617
1668
1606
1664
1598
1653
1581
1590
1511
8
M
aj
or
 A
dv
er
se
 C
ar
di
ov
as
cu
la
r
Ev
en
ts
 (%
)
7
6
4
3
1
5
2
0
0 5 10 15 20 25 30
Bivalirudin alone
Heparin plus GP IIb/IIIa
Days
C
No. at Risk
Bivalirudin alone
Heparin plus
GP IIb/IIIa
1800
1802
1716
1744
1701
1712
1695
1699
1689
1688
1673
1668
1608
1590
5
D
ea
th
 (%
)
4
3
2
1
0
0 5 10 15 20 25 30
Bivalirudin alone
Heparin plus GP IIb/IIIa
Days
D
No. at Risk
Bivalirudin alone
Heparin plus
GP IIb/IIIa
1800
1802
1758
1764
1751
1748
1746
1736
1742
1728
1729
1707
1666
1630
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Stone
2 of 2
05-22-08
ARTIST: ts
35821 ISSUE:
12.2%
9.3%
8.4%
5.0%
5.5%
5.5% 2.9%
1.8%
Cardiac
Noncardiac
0.3%
0.2%
Figure 2. Time-to-Event Curves through 30 Days. 
Time-to-event curves through 30 days are shown for net adverse clinical events (Panel A), major bleeding (Panel B), major adverse car-
diovascular events (Panel C), and death from cardiac and noncardiac causes (Panel D). Treatment with bivalirudin alone as compared 
with heparin plus glycoprotein IIb/IIIa inhibitors resulted in reduced 30-day rates of net adverse clinical events (9.3% vs. 12.2%; hazard 
ratio, 0.75; 95% CI, 0.62 to 0.92; P = 0.006) and major bleeding (5.0% vs. 8.4%; hazard ratio, 0.59; 95% CI, 0.45 to 0.76; P<0.0001), simi-
lar 30-day rates of major adverse cardiovascular events (5.5% and 5.5%, respectively; hazard ratio,1.00; 95% CI, 0.75 to 1.32; P = 0.98), 
and reduced 30-day rates of death from cardiac causes (1.8% vs. 2.9%; hazard ratio, 0.62; 95% CI, 0.40 to 0.96; P = 0.03). P values are 
based on the log-rank test. Event rates represent Kaplan−Meier estimates. GP denotes glycoprotein.
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use of bivalirudin alone, as compared with hepa-
rin plus a glycoprotein IIb/IIIa inhibitor, results in 
significantly reduced 30-day rates of major bleed-
ing and increased event-free survival.
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Table 4. Adverse Events According to Medication Administration before PCI.
Adverse Event
Bivalirudin 
Alone
Heparin plus a 
Glycoprotein  
IIb/IIIa Inhibitor
Relative Risk 
(95% CI)*
P Value for 
Interaction
no./total no. (%)
Major adverse cardiovascular events
Unfractionated heparin before procedure
Yes 54/1182 (4.6) 77/1371 (5.6) 0.81 (0.58−1.14) 0.08
No 44/615 (7.2) 22/427 (5.2) 1.39 (0.85−2.28)
Clopidogrel loading dose
300 mg 43/595 (7.2) 43/618 (7.0) 1.04 (0.69−1.56) 0.76
600 mg 46/1125 (4.1) 47/1091 (4.3) 0.95 (0.64−1.41)
Major bleeding (protocol-defined)
Unfractionated heparin before procedure
Yes 57/1182 (4.8) 117/1371 (8.5) 0.57 (0.42−0.77) 0.47
No 32/615 (5.2) 32/427 (7.5) 0.69 (0.43−1.12)
Clopidogrel loading dose 
300 mg 38/595 (6.4) 64/618 (10.4) 0.62 (0.42−0.91) 0.74
600 mg 47/1125 (4.2) 82/1091 (7.5) 0.56 (0.39−0.79)
* The relative risk is for the patients assigned to receive bivalirudin as compared with those assigned to receive heparin 
plus glycoprotein IIb/IIIa inhibitors. PCI denotes percutaneous coronary intervention.
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cular Research Foundation, New York; F. Feit, New York University, New York; M. Ohman, Duke University Medical Center, Durham, 
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Milan; E. Garcia, Hospital Universitario Gregorio Maranon, Madrid; E. Grube, Heart Center Siegburg, Siegburg, Germany; G. Gua-
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